Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PKM | P14618 | 3/20 | 0.59 |
| ▸ | HTT | P42858 | 2/20 | 0.59 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.59 |
| ▸ | POLB | P06746 | 1/20 | 0.59 |
| ▸ | TSHR | P16473 | 3/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.53 |
| ▸ | MEN1 | O00255 | 3/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.53 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.51 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.51 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.51 |
| ▸ | LMNA | P02545 | 2/20 | 0.50 |
| ▸ | GAA | P10253 | 2/20 | 0.50 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9851568 | 0.89 | PKM (0.63) | PKMHTTALDH1A1POLBTSHR | |
| SCHEMBL18047962 | 0.86 | PKM (0.66) | PKMHTTALDH1A1POLBTSHR | |
| SCHEMBL253492 | 0.86 | PKM (0.59) | PKMHTTALDH1A1POLBTSHR | |
| SCHEMBL5900909 | 0.85 | PKM (0.51) | PKMHTTALDH1A1POLBTSHR | |
| SCHEMBL16572126 | 0.83 | PKM (0.56) | PKMHTTALDH1A1POLBTSHR | |
| SCHEMBL2174608 | 0.83 | TSHR (0.55) | PKMALDH1A1POLBTSHRKMT2A | |
| SCHEMBL14921030 | 0.83 | TSHR (0.55) | HTTALDH1A1POLBTSHRKMT2A | |
| SCHEMBL825032 | 0.82 | PKM (0.59) | PKMHTTALDH1A1POLBTSHR | |
| SCHEMBL825108 | 0.82 | PKM (0.63) | PKMHTTALDH1A1POLBTSHR | |
| SCHEMBL18497968 | 0.81 | PKM (0.54) | PKMHTTALDH1A1POLBTSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230321016-A1 | COMBINATION THERAPY FOR TREATING CANCER | GONGWIN BIOPHARM CO., LTD (TW) | 2023-10-12 | — | — | US | disclosed |
| US-11752118-B2 | Method for treating melanoma | GONGWIN BIOPHARM CO., LTD (TW) | 2023-09-12 | — | — | US | disclosed |
| US-11752160-B2 | Method for reducing fat by administering benzenesulfonamide compositions | GONGWIN BIOPHARM CO., LTD (TW) | 2023-09-12 | — | — | US | disclosed |
| US-9956222-B2 | Quinazoline derivative as tyrosine-kinase inhibitor, preparation method therefor and application thereof | Xuanzhu Pharma Co., Ltd. (CN) | 2018-05-01 | — | — | US | disclosed |
| US-9956222-B2 | Quinazoline derivative as tyrosine-kinase inhibitor, preparation method therefor and application thereof | Xuanzhu Pharma Co., Ltd. (CN) | 2018-05-01 | — | — | US | disclosed |
| US-9782370-B2 | Pharmaceutical compositions of benzenesulfonamide derivatives for treatment of adenoid cystic carcinoma | Gongwin Biopharm Holdings Co., Ltd. (KY) | 2017-10-10 | — | — | US | disclosed |
| US-20170172951-A1 | NOVEL PHARMACEUTICAL COMPOSITIONS OF BENZENESULFONAMIDE DERIVATIVES FOR TREATMENT OF ADENOID CYSTIC CARCINOMA | GONGWIN BIOPHARM CO., LTD. (TAIWAN) (TW) | 2017-06-22 | — | — | US | disclosed |
| US-20170136023-A1 | QUINAZOLINE DERIVATIVE AS TYROSINE-KINASE INHIBITOR, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF | Xuanzhu Pharma Co., Ltd. (CN) | 2017-05-18 | — | — | US | disclosed |
| US-20170136023-A1 | QUINAZOLINE DERIVATIVE AS TYROSINE-KINASE INHIBITOR, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF | Xuanzhu Pharma Co., Ltd. (CN) | 2017-05-18 | — | — | US | disclosed |
| US-20170136023-A1 | QUINAZOLINE DERIVATIVE AS TYROSINE-KINASE INHIBITOR, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF | Xuanzhu Pharma Co., Ltd. (CN) | 2017-05-18 | — | — | US | disclosed |
| EP-2716633-B1 | QUINAZOLINE DERIVATIVE AS TYROSINE-KINASE INHIBITOR, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF | XUANZHU PHARMA CO LTD (CN) | 2017-05-17 | — | — | EP | disclosed |
| EP-2716633-B1 | QUINAZOLINE DERIVATIVE AS TYROSINE-KINASE INHIBITOR, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF | XUANZHU PHARMA CO LTD (CN) | 2017-05-17 | — | — | EP | disclosed |
| US-9586939-B2 | Quinazoline derivative as tyrosine-kinase inhibitor, preparation method therefor and application thereof | Xuanzhu Pharma Co., Ltd. (CN) | 2017-03-07 | — | — | US | disclosed |
| US-9586939-B2 | Quinazoline derivative as tyrosine-kinase inhibitor, preparation method therefor and application thereof | Xuanzhu Pharma Co., Ltd. (CN) | 2017-03-07 | — | — | US | disclosed |
| US-9586939-B2 | Quinazoline derivative as tyrosine-kinase inhibitor, preparation method therefor and application thereof | Xuanzhu Pharma Co., Ltd. (CN) | 2017-03-07 | — | — | US | disclosed |
| US-20140161801-A1 | QUINAZOLINE DERIVATIVE AS TYROSINE-KINASE INHIBITOR, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF | Xuanzhu Pharma Co., Ltd. (CN) | 2014-06-12 | — | — | US | disclosed |
| US-20140161801-A1 | QUINAZOLINE DERIVATIVE AS TYROSINE-KINASE INHIBITOR, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF | Xuanzhu Pharma Co., Ltd. (CN) | 2014-06-12 | — | — | US | disclosed |
| US-20140161801-A1 | QUINAZOLINE DERIVATIVE AS TYROSINE-KINASE INHIBITOR, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF | Xuanzhu Pharma Co., Ltd. (CN) | 2014-06-12 | — | — | US | disclosed |
| WO-2013013504-A1 | TIGECYCLINE DERIVATIVE | 山东亨利医药科技有限责任公司 (CN) | 2013-01-31 | — | — | WO | disclosed |
| WO-2012159457-A1 | QUINAZOLINE DERIVATIVE AS TYROSINE-KINASE INHIBITOR, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF | 山东亨利医药科技有限责任公司 (CN) | 2012-11-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170136023-A1 | QUINAZOLINE DERIVATIVE AS TYROSINE-KINASE INHIBITOR, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF | JAK1, JAK2, YES1 | PKM 1041/4885HTT 3051/4885ALDH1A1 3164/4885 |
| US-20170172951-A1 | NOVEL PHARMACEUTICAL COMPOSITIONS OF BENZENESULFONAMIDE DERIVATIVES FOR TREATMENT OF ADENOID CYSTIC CARCINOMA | ABCD3, CFTR, ADSL | PKM 3549/4885HTT 2849/4885ALDH1A1 1243/4885 |
| US-11752160-B2 | Method for reducing fat by administering benzenesulfonamide compositions | LIPE, FABP4, LIPA | PKM 521/4885HTT 814/4885ALDH1A1 728/4885 |
| US-20230321016-A1 | COMBINATION THERAPY FOR TREATING CANCER | TP53, MCL1, TOP2B | PKM 2022/4885HTT 3302/4885ALDH1A1 381/4885 |
| US-11752118-B2 | Method for treating melanoma | TYR, MITF, BRAF | PKM 1050/4885HTT 3063/4885ALDH1A1 528/4885 |
| US-20140161801-A1 | QUINAZOLINE DERIVATIVE AS TYROSINE-KINASE INHIBITOR, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF | JAK1, JAK2, YES1 | PKM 1041/4885HTT 3051/4885ALDH1A1 3164/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.